MITCHELL GLASS
Medical Practice in Wilmington, DE
License number
Pennsylvania MD022820E
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Wilmington, DE 19806
Pennsylvania
Pennsylvania
Personal information
See more information about MITCHELL GLASS at radaris.comName
Address
Phone
730 Merwin Rd, New Kensingtn, PA 15068
730 Merwin Rd, Lower Burrell, PA 15068
902 Broom St, Wilmington, DE 19806
902 Broom St, Wilmington, DE 19806
New Kensington, PA
Professional information
See more information about MITCHELL GLASS at trustoria.com
Therapeutic Agent For The Prevention Or Treatment Of Adult Respiratory Distress Syndrome
Therapeutic Agent For The Prevention Or Treatment Of Adult Respiratory Distress Syndrome
US Patent:
5338727, Aug 16, 1994
Filed:
Aug 3, 1992
Appl. No.:
7/924686
Inventors:
Mitchell Glass - Wilmington DE
Joseph C. Williams - Elkton MD
Ross L. Stein - Scotch Plains NJ
Joseph C. Williams - Elkton MD
Ross L. Stein - Scotch Plains NJ
Assignee:
Imperial Chemical Industries PLC - Millbank
International Classification:
A61K 3702
US Classification:
514 19
Abstract:
There is provided a novel therapeutic agent for use in the prevention or treatment of adult respiratory distress syndrome and for use in the manufacture of a medicament for the prevention or treatment of adult respiratory distress syndrome, as well as a method of prevention or treatment of adult respiratory distress syndrome with the therapeutic agent and a method of treatment of cystic fibrosis with the therapeutic agent in combination with one or more other agents indicated for the treatment of adult respiratory distress syndrome.
Agent For Therapy
Agent For Therapy
US Patent:
5128322, Jul 7, 1992
Filed:
Jun 25, 1991
Appl. No.:
7/720557
Inventors:
Mitchell Glass - Wilmington DE
Assignee:
Imperial Chemical Industries plc - London
International Classification:
C07K 506, A61K 3764, A61K 3702
US Classification:
514 19
Abstract:
There is provided a novel therapeutic agent for use in the prevention or treatment of hemorrhage associated with acute nonlymphocytic leukemia or its therapy, as well as a method of prevention or treatment of hemorrhage associated with acute nonlymphocytic leukemia or its therapy with the therapeutic agent, and a method of prevention or treatment of hemorrhage associated with acute nonlymphocytic leukemia or its therapy with the therapeutic agent in combination with one or more other agents indicated for the treatment of acute nonlymphocytic leukemia.
Treatment Of Cystic Fibrosis
Treatment Of Cystic Fibrosis
US Patent:
5162348, Nov 10, 1992
Filed:
May 24, 1990
Appl. No.:
7/528656
Inventors:
Mitchell Glass - Wilmington DE
Assignee:
Imperial Chemical Industries PLC - London
International Classification:
A61K 3141
US Classification:
514359
Abstract:
There is provided a novel therapeutic product for use in the symptomatic treatment of cystic fibrosis and for use in the manufacture of a medicament for the treatment of cystic fibrosis, as well as a method for treatment of cystic fibrosis with the therapeutic product and a method of treatment of cystic fibrosis with the therapeutic product in combination with one or more other agents indicated for the treatment of cystic fibrosis.
Use Of Beta-Adrenergic Inverse Agonists For Smoking Cessation
Use Of Beta-Adrenergic Inverse Agonists For Smoking Cessation
US Patent:
2013029, Nov 7, 2013
Filed:
Jan 9, 2012
Appl. No.:
13/978845
Inventors:
Richard A. Bond - San Francisco TX, US
Mitchell Glass - Wilmington DE, US
Mitchell Glass - Wilmington DE, US
Assignee:
INVION LIMITED
International Classification:
A61K 31/138, A61K 45/06
US Classification:
424 48, 514651, 514411, 514171, 514367, 514250, 514398
Abstract:
The chronic use of p-adrenergic inverse agonists such as nadolol, carvedilol, and ICI-118,551 provides an improved method for the treatment of mucus hypersecretion in subjects with such mucus hypersecretion. One aspect of a method according to the present invention is a method of preventing or controlling mucus hypersecretion in the respiratory tract comprising administering a therapeutically effective quantity of a p-adrenergic inverse agonist to a subject with mucus hypersecretion or at risk of mucus hypersecretion. The invention further encompasses pharmaceutical compositions comprising the p-adrenergic inverse agonist and the additional compound.